Peficitinib is a JAK1/2/3 and TYK2 inhibitor, approved in Japan in 2019 for rheumatoid arthritis after Phase III clinical trials demonstrated a reduction in symptoms and minimal toxicity compared to placebo in clinical trials[167,168]. This evidence concerns the gene JAK1 and rheumatoid arthritis.